Skip to main content
Quest Diagnostics

Increases in Glycated Hemoglobin (HbA1c) Testing Following Expanded Medicare Screening Coverage

ADA 2026

New Orleans, LA, June 5-8, 2026

Poster presentation: Increases in Glycated Hemoglobin (HbA1c) Testing Following Expanded Medicare Screening Coverage

Authors: Szymonifka J, Chen Z, Warren f, Ng J, Dixit SB

Medical Specialty: Endocrinology, Cardiology, Cardiovascular disease

Related content

Audio Podcast
Action From Insight: Tackling Insulin Resistance
Publication
Contributions of Glucose and Hemoglobin A1c Measurements in Diabetes Screening
Publication
Insulin Resistance is Associated with Incident Prediabetes and Type 2 Diabetes in Normoglycemic Individuals
Publication
Glycemic Control in Patients with Employer-Sponsored Health Benefits
Publication
The Laboratory Billing Process and Its Applications to Molecular Microbiology Testing: Guidance for Laboratorians
Publication
Contributions of Glucose and Hemoglobin A1c Measurements in Diabetes Screening

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.